RSS 1.0Division of Hematology / Oncology
The Division of Hematology and Oncology conducts research and treats all types of adult cancers including solid tumor cancers and hematological (blood) disorders, as well as coagulation disorders and non-cancerous blood diseases. With over 80 faculty members representing a broad range of professional training and expertise, our dedicated team of professionals is committed to cancer care through research to better understand and treat cancers; state-of-the-art patient care and personalized cancer therapy; clinical trials, including Phase I drug development with subsequent Phase II and Phase III testing; training future cancer doctors and researchers; and cancer chemotherapy, pharmacology, and biological therapy with an emphasis on solid tumors.
Collections in this community
Recent Submissions
-
(Blood Cancer Journal, 2023-01-04)Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic ...
-
(Cell Death & Disease, 2023-01-16)Tumor growth, metastasis and therapeutic response are believed to be regulated by the tumor and its microenvironment (TME) in advanced renal cell carcinoma (RCC). However, the mechanisms underlying genomic, transcriptomic ...
-
(Annals of Oncology, 2020-02)Background: The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 ...
-
(Leukemia, 2020-09)Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, ...
-
(Journal of Thoracic Oncology, 2020-03)Introduction: Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, ...
-
(Research and Practice in Thrombosis and Haemostasis, 2020-02)Background Clinical application of population pharmacokinetics (popPK) is of increasing interest to patients with hemophilia, providers, and payers. Routine use of popPK profiles in factor replacement prophylaxis decision ...
-
(Molecular Oncology, 2020-02)The development of pulmonary metastasis is the leading cause of death in osteosarcoma (OS), which is the most common malignant bone tumor in children. We have previously reported that the tumor suppressor p27 (KIP1, CDKN1B) ...
-
Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study (Hereditary Cancer in Clinical Practice, 2019-12-16)Background Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome. This study assesses trends in diagnosis of LS and adherence to recommended LS-related care in a large integrated healthcare ...
-
(Breast Cancer Research, 2019-12-19)Background: Heterogeneity of immune gene expression patterns of luminal breast cancer (BC), which is clinically heterogeneous and overall considered as low immunogenic, has not been well studied especially in non-European ...
-
(Molecular & Cellular Oncology, 2020-03-03)The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated - but currently undruggable - ...
-
(Intenational Journal of Cancer, 2020-03-01)We previously identified a novel breast cancer susceptibility variant on chromosome 4q31.22 locus (rs1429142) conferring risk among women of European ancestry. Here, we report replication of findings, validation of the ...
-
(Annals of Oncology, 2019-07)Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI) specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating mutations or EGFR T790M resistance ...
-
(Annals of Hematology, 2019-10)Hematopoietic stem cell transplantation (HSCT) is considered an effective way to prevent relapse in adults with acute lymphoblastic leukemia (ALL). This study aimed to assess general trends in the use of various types of ...
-
(Oncologist, 2019-10)Drawing on discussions at a workshop hosted by the National Cancer Policy Forum, current challenges in pathology are reviewed and practical steps to facilitate high‐quality cancer diagnosis and care through improved patient ...
-
(CANCER CONTROL, 2019-07-23)Accurate public perceptions on the risk factors associated with cancer are important in promoting primary, secondary, and tertiary prevention. Limited studies have explored this topic among patients with cancer in non-western, ...
-
(Cancer Control, 2019-07-19)Anxiety, a condition which is commonly found in patients with cancer, has negative impacts on their quality of life and treatment outcome. This study aimed to determine the level of anxiety in patients with cancer and ...
-
(Cancer Contol, 2019-07-22)The population size and projected demographics of Vietnam's 2 largest cities, Ho Chi Minh City (HCMC) and Hanoi, will change dramatically over the next decade. Demographic changes in an aging population coupled with income ...
-
(NPJ Breast Cancer, 2019-07-25)TP53 mutations are common in breast cancer and are typically associated with more aggressive tumor characteristics, but little is known about the clinicopathological and epidemiological relevance of p53 protein expression, ...
-
(Blood Advances, 2019-06-25)HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal ...
-
(JCO Precision Oncology, 2019-06-27)PURPOSE To study whether BRAF V600 mutations in non-small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) ...